Search alternatives:
nm decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
nm decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
321
-
322
-
323
Data_Sheet_1_Marathon Running Increases Synthesis and Decreases Catabolism of Joint Cartilage Type II Collagen Accompanied by High-Energy Demands and an Inflamatory Reaction.PDF
Published 2021“…Mean sC2C levels (220.83 ± 39.50 ng/ml) decreased post-race (188.67 ± 38.52 ng/ml) (p = 0.002). …”
-
324
-
325
Bumblebees were subjected to 5 day exposure to Imidacloprid and/or/none twice daily 670 nm.
Published 2021“…As with respiration we then asked what 670nm duration was needed for correction B. Bumblebees (≥ 20 bees per group) maintained on Imidacloprid were exposed to 670nm light for 0.5, 1, 5, 15 or 60mins. …”
-
326
-
327
-
328
-
329
-
330
Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease
Published 2025“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC<sub>50</sub> = 0.1 nM, msEH IC<sub>50</sub> = 0.1 nM). …”
-
331
Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease
Published 2025“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC<sub>50</sub> = 0.1 nM, msEH IC<sub>50</sub> = 0.1 nM). …”
-
332
Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease
Published 2025“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC<sub>50</sub> = 0.1 nM, msEH IC<sub>50</sub> = 0.1 nM). …”
-
333
Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease
Published 2025“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC<sub>50</sub> = 0.1 nM, msEH IC<sub>50</sub> = 0.1 nM). …”
-
334
-
335
Annual number of outpatient visits in recurrence and non-recurrence groups.
Published 2025“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
336
Annual treatment frequencies in all eyes.
Published 2025“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
337
Annual number of outpatient visits in all eyes.
Published 2025“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
338
Annual treatment frequencies in recurrence and non-recurrence groups.
Published 2025“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
-
339
-
340